Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nucleic acid immunization: a prophylactic gene therapy?

K Cichutek1

  • 1Department of Biotechnology, Paul-Ehrlich-Institute, Langen, Germany.

Vaccine
|December 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Special considerations for the regulation of biological medicinal products in individualised medicine. More than stratified medicine].

Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·2013
Same author

RNAi-mediated gene silencing in tumour tissue using replication-competent retroviral vectors.

Gene therapy·2011
Same author

Relevance of an academic GMP Pan-European vector infra-structure (PEVI).

Current gene therapy·2010
Same author

[The framework is established: progress in gene therapy, cell therapy and tissue engineering medicine].

Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·2010
Same author

Pseudotyping lentiviral vectors with the wild-type measles virus glycoproteins improves titer and selectivity.

Gene therapy·2009
Same author

Cell entry targeting restricts biodistribution of replication-competent retroviruses to tumour tissue.

Gene therapy·2008
Same journal

Immunity gaps for several vaccine preventable diseases in Norway.

Vaccine·2026
Same journal

Australians' attitudes to mRNA vaccination in humans and animals: A cross-sectional survey.

Vaccine·2026
Same journal

Immunoproteomics and reverse vaccinology identify a protective T-cell epitope from Fonsecaea pedrosoi for experimental chromoblastomycosis.

Vaccine·2026
Same journal

Retraction notice to "Effectiveness of prescription-based influenza vaccination services among older adults in Binzhou, China: A cluster-randomized controlled trial" [Vaccine 82 (2026) 128588].

Vaccine·2026
Same journal

Barriers and facilitators to COVID-19 vaccination programme implementation in Ireland: a qualitative study of implementation stakeholders using CFIR.

Vaccine·2026
Same journal

Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study.

Vaccine·2026
See all related articles

Nucleic acid (NA) vaccines offer safety and cellular immune response benefits. German Gene Law regulates preclinical NA vaccine experiments, while EU regulations cover production and marketing authorization for human use.

Area of Science:

  • Biotechnology
  • Vaccinology
  • Molecular Biology

Background:

  • Nucleic acid (NA) vaccines combine safety of subunit/inactivated vaccines with advantages of live recombinant vaccines.
  • NA vaccines can induce a protective cellular immune response.
  • German Gene Law regulates genetic modification for recombinant NA vaccine construction.

Purpose of the Study:

  • To discuss the regulatory landscape for NA vaccines in Germany and the European Union.
  • To outline guidelines for the production and preclinical safety testing of NA vaccines.
  • To present a model for an NA vaccine against AIDS using a simian immunodeficiency provirus.

Main Methods:

  • Review of German Gene Law and European Union guidelines for gene therapeutics and NA vaccines.

Related Experiment Videos

  • Examination of regulatory frameworks for biotechnological products.
  • Investigation of a model NA vaccine for AIDS at the Paul-Ehrlich-Institute.

    • Main Results:

    • Preclinical laboratory experiments involving NA vaccines are regulated by the Gene Law in Germany.
    • NA vaccines are considered biotechnological products subject to EU marketing authorization procedures.
    • A model NA vaccine for AIDS is under investigation, utilizing a defective simian immunodeficiency provirus.

    Conclusions:

    • NA vaccines present a promising approach with potential for broad applications.
    • Regulatory frameworks are evolving to accommodate the development and approval of NA vaccines.
    • Ongoing research, including animal model studies, is crucial for advancing NA vaccine technology.